NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Metropolis H1 FY27 Revenue Up 16.2%, EBITDA Margin Expands 190 bps to 26.2%
Metropolis Healthcare released its Q2/H1 FY27 earnings call transcript, highlighting organic revenue growth of 16.2% for the first half, up from 12%-13% in prior years. First-half EBITDA margin expanded by 190 bps to 26.2% without any price increases. Patient volume growth accelerated to 10% compared to 7% a year ago, driven by maturation of centers in Tier 2/3 towns. Tier 3 markets are growing at around 20% and now contribute 26% of overall revenue, with management planning potential B2C price revisions in early calendar year 2027.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the complete earnings conference call transcript for Q2 and H1 FY27 held on November 04, 2026.
ஏன் இது முக்கியம்Confirms strong operating leverage with volume growth accelerating to 10% and Tier 3 markets becoming a primary driver without pricing headwinds from government regulations.
📅 குறுகிய காலம்Neutral to mildly positive as the transcript reinforces healthy underlying volume trends and margin expansion reported in the Q2 results.
📈 நீண்ட காலம்Structural tailwinds include network expansion in Tier 2/3 markets aided by digital authorization of reports by pathologists, alongside potential growth from ancillary healthcare services.
⚠ அபாய எச்சரிக்கைகள்
Weak monsoon or seasonal volatility dampening acute testing volumes
Execution risks in planned price hikes amid competitive market dynamics
👀 கவனிக்க வேண்டியவை
Track the implementation and margin impact of the proposed early-2027 price revisions, as well as the rollout and monetization of asset-light preventive care pilot programs.
Q2 FY27 PAT Jumps 43% YoY to ₹75 Cr, Revenue Rises 16% to ₹497 Cr
Metropolis Healthcare reported a 15.8% YoY growth in consolidated revenue from operations to ₹496.8 crore for Q2 FY27. Reported EBITDA rose 23.9% YoY to ₹134.9 crore with margins expanding 180 bps to 27.2%. Profit After Tax (PAT) grew 42.7% YoY to ₹75.5 crore, supported by volume growth and premiumisation. Additionally, the Board declared an interim dividend of ₹1 per share.
உச்சம் நம்பிக்கை
என்ன மாறியதுAnnouncement of unaudited consolidated Q2 FY27 financial performance and declaration of an interim dividend of ₹1 per share.
ஏன் இது முக்கியம்Demonstrates operating leverage and pricing power via test mix, as revenue per patient rose 6% without direct price increases, driving faster profit growth than top-line.
Q2 FY27 Revenue: ₹496.8 கோடிQ2 FY27 EBITDA Margin: 27.2%Q2 FY27 PAT: ₹75.5 கோடிInterim Dividend: ₹1 per shareQ2 வருவாய் vs TTM வருவாய்: ~29.1%
📅 குறுகிய காலம்Strong operational beat on EBITDA margins and PAT is likely to be received positively by the market in the immediate term.
📈 நீண்ட காலம்Expansion into specialized genomics and premium wellness segments (TruHealth) combined with volume-led tier-3 town expansion supports structural compounding in the diagnostic chain sector.
⚠ அபாய எச்சரிக்கைகள்
Intensifying competition from health-tech and regional hospital chains limiting pricing power
Integration risks from ongoing bolt-on acquisitions
👀 கவனிக்க வேண்டியவை
Track whether EBITDA margins sustain above 26-27% in upcoming quarters without price hikes, and monitor volume expansion across Tier II and III towns under the Metropolis 3.0 strategy.
Metropolis Q2 Standalone PAT Jumps 47.4% YoY to ₹68.75 Cr; Declares ₹1/Share Interim Dividend
Metropolis Healthcare reported its Q2 FY27 (quarter ended September 30, 2026) standalone results, with revenue from operations growing 17.3% YoY to ₹416.93 Cr compared to ₹355.46 Cr in Q2 FY26. Standalone profit after tax increased by 47.4% YoY to ₹68.75 Cr from ₹46.63 Cr. Half-year operating cash flows also improved strongly, reaching ₹222.68 Cr against ₹129.13 Cr in H1 FY26. Additionally, the Board declared an interim dividend of ₹1 per equity share (face value ₹2) with a record date of November 09, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுMetropolis approved its Q2 FY27 financial results showing double-digit revenue growth and healthy margin expansion, accompanied by a ₹1/share interim dividend declaration.
ஏன் இது முக்கியம்Demonstrates operating leverage and pricing resilience in core diagnostic markets despite competitive pressures, with cash generation driving dividend payouts.
Standalone Revenue (Q2 FY27): ₹416.93 கோடிStandalone PAT (Q2 FY27): ₹68.75 கோடிInterim Dividend per share: ₹1.00Interim Dividend Record Date: நவம்பர் 09, 2026H1 FY27 Consolidated CFO: ₹222.68 கோடி
📅 குறுகிய காலம்Positive sentiment likely driven by the 47% YoY jump in standalone net profit and immediate shareholder return via the interim dividend.
📈 நீண்ட காலம்Structural tailwinds continue from market consolidation into organized diagnostics, supported by robust operating cash flow generation.
⚠ அபாய எச்சரிக்கைகள்
Intensifying competition from health-tech platforms and hospital chains impacting regional pricing power
👀 கவனிக்க வேண்டியவை
Monitor whether the volume growth and operating leverage seen in high-volume Q2 sustain into H2, alongside progress on the 'Metropolis 3.0' expansion strategy.
Metropolis Reports ~15% YoY Revenue Growth for Q2FY27 with Margin Expansion
Metropolis Healthcare released its Q2FY27 business update reporting consolidated revenue growth of approximately 15% YoY. The performance was anchored by double-digit patient and test volume growth alongside improved realizations and a favorable product mix. TruHealth Wellness and Specialty segments were the fastest-growing categories during the quarter. Furthermore, EBITDA margins improved meaningfully on both a YoY and QoQ basis due to operating leverage and operational efficiencies.
உச்சம் நம்பிக்கை
என்ன மாறியதுMetropolis shared preliminary operating trends for Q2FY27 ahead of full audited financial results.
ஏன் இது முக்கியம்A 15% YoY revenue growth paired with margin expansion indicates sustained demand and operating leverage, following a base of Rs 429.2 Cr revenue in Q2FY26 (Sep 2025).
YoY Revenue Growth: ~15%Volume Growth: double digitPrevious Year Q2 Revenue (Sep 2025): Rs 429.19 கோடி
📅 குறுகிய காலம்Positive sentiment likely in the near term as volume growth returns to double digits with sequential and yearly margin expansion.
📈 நீண்ட காலம்Expansion in high-margin TruHealth wellness and specialty segments supports Metropolis's 3.0 strategy and structural margin resilience.
⚠ அபாய எச்சரிக்கைகள்
Final audited figures and exact EBITDA margins are yet to be approved by the Board
👀 கவனிக்க வேண்டியவை
Track the detailed Q2FY27 financial results and investor presentation for exact margin expansion numbers, realization per patient, and full audited figures.
Metropolis Guides 14–15% FY27 Growth, Targets 27–28% EBITDA Margin Over 3 Years
Metropolis Healthcare presented its 3-year strategic roadmap at its Analyst Meet, reaffirming an FY27 revenue growth guidance of 14–15% with a 100–150 bps margin improvement after delivering ₹450 Cr revenue (+17% YoY) in Q1 FY27. Over the next three years, the company aims to expand EBITDA margins from 24.4% to 27–28%, driven by network density, specialty test mix (aiming for 45% of revenue), and the turnaround of Core Diagnostics (targeting 20%+ margin by Year 3). Capex is guided to remain asset-light at ~4% of revenue, supporting balance sheet efficiency and ROCE expansion.
உச்சம் நம்பிக்கை
என்ன மாறியதுMetropolis released its 2026 Analyst Meet presentation detailing 3-year targets, volume-led growth expectations, and margin expansion levers.
ஏன் இது முக்கியம்Provides visibility into management's mid-term targets, highlighting disciplined capital allocation (capex ~4% of revenue) and margin accretion via specialty diagnostics and M&A integration.
📅 குறுகிய காலம்Informational presentation; provides clarity on full-year targets and confirms positive operating momentum seen in Q1 FY27.
📈 நீண்ட காலம்Execution on expanding the centre-to-lab ratio to 35:1 and turning around Core Diagnostics could structurally support operating margins and ROCE compounding.
⚠ அபாய எச்சரிக்கைகள்
Execution risk on turnaround of acquired assets (Core Diagnostics) to reach 20%+ margin
Intense competitive pricing pressure from regional and digital diagnostic aggregators
👀 கவனிக்க வேண்டியவை
Track quarterly revenue trajectory against the 14–15% annual guidance and monitor progress on EBITDA margin expansion toward the 27–28% target in upcoming quarters.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
17% Q1 Revenue Growth; Metropolis Targets 27-28% EBITDA Margin in 2 Years
Metropolis Healthcare reported a strong Q1 FY27 with ~17% YoY revenue growth, exceeding its previous guidance. Management has maintained a full-year revenue growth outlook of 14-15%, primarily driven by volume growth in Tier-2 and Tier-3 markets. A key focus is margin expansion, with a targeted 100-150 bps improvement in EBITDA for FY27 and a long-term goal of 27-28%. The integration of Core Diagnostics is progressing, with margins currently at ~8% and a target of 25% within 3-4 years.
உச்சம் நம்பிக்கை
என்ன மாறியதுMetropolis has shifted from an integration phase to a margin-expansion phase, backed by a Q1 revenue beat and specific margin improvement targets.
ஏன் இது முக்கியம்The diagnostic industry is seeing a shift toward organized players; Metropolis's ability to expand margins while growing volumes by 14-15% is critical for valuation re-rating.
📅 குறுகிய காலம்Positive sentiment expected as the company exceeded revenue guidance and provided a clear roadmap for margin recovery.
📈 நீண்ட காலம்Structural growth in specialty diagnostics (2,200+ tests) and expansion into 800 towns support long-term volume-led growth.
⚠ அபாய எச்சரிக்கைகள்
Intensifying competition from health-tech platforms could pressure pricing by 5-10%
Execution risk in scaling Core Diagnostics margins from 8% to 25%
👀 கவனிக்க வேண்டியவை
Monitor the volume growth trajectory in Tier-2/3 cities and the quarterly progression of EBITDA margins toward the 27-28% target to validate operating leverage claims.
Metropolis Healthcare reported a strong start to FY27 with revenue growing 16.6% YoY to ₹450.2 crore, driven by a 10% increase in patient volumes. Profitability improved significantly as EBITDA rose 27.1% YoY to ₹113.2 crore, resulting in a 210 bps margin expansion to 25.2%. The growth was broad-based, with B2C revenue up 18% and Tier III cities growing at 25% YoY. PAT increased by 25.8% to ₹56.9 crore, reflecting strong operating leverage and a richer test mix.
உச்சம் நம்பிக்கை
என்ன மாறியதுMetropolis reported its Q1FY27 financial results, showing double-digit growth in revenue and profit with significant margin improvement compared to the previous year.
ஏன் இது முக்கியம்The results demonstrate the company's ability to drive volume-led growth and margin expansion without price hikes, highlighting brand strength and operational efficiency despite intensifying competition in the diagnostic sector.
Revenue (Q1FY27): ₹450.2 கோடிEBITDA லாப வரம்பு: 25.2%PAT Growth (YoY): 25.8%Revenue vs TTM Revenue: ~27.3%TruHealth Revenue: ₹81 கோடி
📅 குறுகிய காலம்The stock may see positive sentiment in the coming days as the 25.2% EBITDA margin exceeds the TTM OPM of 24.4%, indicating improved operational efficiency.
📈 நீண்ட காலம்Structural growth remains tied to deeper penetration in Tier III towns and the shift of market share from unorganized to organized players through the Metropolis 3.0 strategy.
⚠ அபாய எச்சரிக்கைகள்
Intensifying competition from large conglomerates and health-tech platforms
Potential pricing pressure in the wellness segment
Integration risks of bolt-on acquisitions
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of volume-led growth in Tier III markets and the execution of the 'Metropolis 3.0' strategy, particularly the integration of acquisitions like Core Diagnostics.
17% Revenue Growth and 27% EBITDA Growth in Q1 FY27; Margins Expand to 25.2%
Metropolis Healthcare reported a strong Q1 FY27 with revenue reaching INR 450.2 Cr, a 17% YoY increase driven by volume growth rather than price hikes. EBITDA grew 27% YoY to INR 113.2 Cr, with margins expanding by 210 bps to 25.2% due to operating leverage and automation. Patient volumes rose 10% to 3.7 million, while the high-margin TruHealth (wellness) segment grew 22%. The company is successfully executing its 'Metropolis 3.0' strategy, with Tier-3 city revenue growing significantly by 25% YoY.
உச்சம் நம்பிக்கை
என்ன மாறியதுMetropolis has shifted to a volume-led growth model (10% patient growth) without relying on price hikes, while simultaneously expanding margins through automation and network rationalization.
ஏன் இது முக்கியம்The results demonstrate strong execution of the 'Metropolis 3.0' strategy, proving the company can scale in fragmented markets (Tier-3) and high-margin segments (Wellness/Specialty) despite intense industry competition.
Q1 வருவாய்: INR 450.2 CrQ1 வருவாய் vs TTM வருவாய்: 27.3%EBITDA லாப வரம்பு: 25.2%Patient Volume Growth: 10% YoYService Network: 5,003 points
📅 குறுகிய காலம்The stock may see positive momentum in the coming weeks as the market reacts to the margin expansion and robust volume-led revenue growth that outperformed previous guidance.
📈 நீண்ட காலம்The structural shift toward organized diagnostic chains and the company's expansion into Genomics and Radiology provide a clear path for sustained double-digit growth over the next 3-5 years.
⚠ அபாய எச்சரிக்கைகள்
Intensifying competition from large conglomerates and health-tech platforms
Geographic concentration with 50% revenue still coming from West India
Potential 5-10% pricing pressure in routine testing
👀 கவனிக்க வேண்டியவை
Watch for the sustainability of double-digit volume growth in Tier-3 markets and the impact of competitive pricing from health-tech platforms on long-term margins. Monitor the integration of the Core Diagnostics menu and its contribution to specialty testing revenue.
Metropolis Q1 FY27: Net Profit Rises 42% YoY to ₹50.6 Cr; Revenue Up 15%
Metropolis Healthcare reported a strong performance for Q1 FY27, with consolidated revenue growing 15.2% YoY to ₹372.3 Cr. Net profit surged 42.2% YoY to ₹50.6 Cr, significantly outpacing revenue growth and indicating improved operating leverage. On a sequential basis, revenue grew 5.8% compared to the March 2026 quarter. The company also noted a two-month delay in the internal transfer of its Quality Assessment business to a wholly-owned subsidiary.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its first-quarter results for FY27, showing double-digit growth in revenue and a substantial jump in profitability compared to the same period last year.
ஏன் இது முக்கியம்The results demonstrate strong pricing power and operational efficiency in a competitive diagnostic market. The profit growth outperforming revenue growth suggests that the company is successfully managing its cost base while scaling volumes.
📅 குறுகிய காலம்The stock is likely to react positively in the short term due to the significant earnings beat and margin expansion compared to the previous year.
📈 நீண்ட காலம்The company's focus on specialized segments like Genomics and Radiology, combined with its 'T3 Acceleration' strategy, supports a structural growth outlook for the organized diagnostic sector.
⚠ அபாய எச்சரிக்கைகள்
Intensifying competition from health-tech platforms and large conglomerates
Delay in internal business restructuring (Quality Assessment business transfer)
👀 கவனிக்க வேண்டியவை
Investors should monitor if the high profit growth rate is sustainable through the high-volume Q2 period. Watch for updates on the integration of recent acquisitions and the execution of the 'Metropolis 3.0' strategy in the Top 800 towns.
16% YoY Revenue Growth in Q1FY27; Wellness and Specialty Segments Lead Performance
Metropolis Healthcare reported a healthy ~16% YoY revenue growth for Q1FY27, primarily driven by increased patient volumes and improved realizations from a better product mix. The TruHealth Wellness and Specialty segments were the fastest-growing areas during the quarter. EBITDA margins improved on a year-on-year basis, meeting management guidance, while remaining stable compared to the previous quarter (Q4FY26). Both B2C and B2B segments showed volume growth, supported by network expansion and higher wallet share from existing customers.
உச்சம் நம்பிக்கை
என்ன மாறியதுThis filing provides a preliminary business update for Q1FY27, indicating double-digit revenue growth and margin improvement ahead of the formal earnings release.
ஏன் இது முக்கியம்The 16% growth suggests that Metropolis is successfully navigating competitive pressures from health-tech platforms while shifting its mix toward higher-margin wellness and specialty testing.
📅 குறுகிய காலம்The stock may see positive sentiment in the coming days as the 16% growth rate and margin improvement signal a strong start to the new fiscal year.
📈 நீண்ட காலம்The focus on 'Metropolis 3.0' and expansion into high-science domains like Genomics and Wellness is structurally positive for long-term realizations and market share.
⚠ அபாய எச்சரிக்கைகள்
Intensifying competition from large conglomerates and health-tech platforms
Potential pricing pressure of 5-10% in the diagnostic industry
👀 கவனிக்க வேண்டியவை
Investors should wait for the detailed Q1FY27 financial results to confirm the exact EBITDA margin expansion and assess the impact of the Core Diagnostics acquisition on the bottom line.
Metropolis FY26 Organic Revenue Up 13.7%; Targets 27-28% EBITDA Margin in 3 Years
Metropolis Healthcare reported a strong FY26 with organic revenue growth of 13.7%, exceeding its guidance of 12-13%. The company successfully integrated Core Diagnostics, turning its EBITDA from -2% to high-single digits in Q4 FY26. Management has provided a robust 3-year outlook targeting a revenue CAGR of 14-15% and group EBITDA margins of 27-28%. Additionally, the board recommended an interim dividend of INR 1 per share, following a bonus issue in March 2026.
முக்கிய அம்சங்கள்
Organic revenue grew 13.7% in FY26, with normalized organic margins expanding 140 bps to 25.9%.Core Diagnostics integration achieved high-single-digit EBITDA in Q4, on track for 20% plus target in 3 years.North India revenue contribution increased to 17%, while digital channels now account for 25% of total revenue.Expansion plan includes adding 1,500 collection centers and 100 mini hubs (pathology + radiology) over 3 years.B2C segment remains strong at 60% of total revenue with self-referrals contributing 40%.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the margin expansion and the successful turnaround of Core Diagnostics. The clear 3-year growth roadmap and focus on high-margin specialty genomics make it a strong candidate for long-term portfolios.
Metropolis Healthcare Corrects FY25 Comparative Profit Figures; FY26 Standalone PAT at ₹157.5 Cr
Metropolis Healthcare issued a correction to its May 13, 2026, financial results filing due to an inadvertent error in the comparative profit figures for the quarter ended March 31, 2025. The company clarified that this administrative correction is non-material and has no impact on the current financial year's performance. For the full year FY26, the company reported a standalone revenue of ₹1,365.5 crore, a 12.3% increase over FY25. Standalone net profit for FY26 rose to ₹157.5 crore, up from ₹124.8 crore in the previous fiscal year.
முக்கிய அம்சங்கள்
FY26 Standalone Revenue grew 12.3% YoY to ₹1,36,547.17 Lakhs.Standalone Net Profit for FY26 increased to ₹15,748.33 Lakhs from ₹12,479.60 Lakhs in FY25.Q4 FY26 Standalone Revenue stood at ₹35,203.12 Lakhs compared to ₹31,168.61 Lakhs in Q4 FY25.The administrative correction pertains only to the comparative Q4 FY25 profit figure and does not affect FY26 results.Basic EPS for FY26 improved to ₹7.60 from ₹6.01 in the previous year.
👀 கவனிக்க வேண்டியவை
Investors should focus on the healthy 12.3% revenue growth and significant profit expansion in FY26, as the reported correction is purely administrative and pertains to historical data. The underlying business performance remains robust with improving margins.
Metropolis Q4FY26: PAT jumps 75% YoY to ₹51 Cr, EBITDA up 71%; ₹1 Dividend declared
Metropolis Healthcare reported a strong Q4FY26 with revenue growing 23% YoY to ₹425 Cr, driven by an 11% increase in patient volumes. Profitability saw a significant boost with PAT rising 75% YoY to ₹51 Cr and EBITDA margins expanding to 25.4% from 18.5% in the previous year. The company successfully crossed the 5,000-center milestone and saw robust growth in both B2C (20%) and B2B (28%) segments. Additionally, the board has recommended a dividend of ₹1 per share.
முக்கிய அம்சங்கள்
Revenue grew 23% YoY to ₹425 Cr, while PAT surged 75% YoY to ₹51 Cr.EBITDA increased by 71% YoY to ₹108 Cr with margins expanding to 25.4% from 18.5%.Patient volumes and test volumes grew by 11% and 14% YoY, respectively.B2B revenues showed strong growth of 28% YoY, while B2C revenues grew by 20%.The company reached a milestone of 5,000+ centers and declared a ₹1 dividend per share.
👀 கவனிக்க வேண்டியவை
The significant margin expansion and double-digit volume growth suggest strong operational leverage and market share gains. Investors should maintain a positive outlook while watching for the sustainability of these high margins in a competitive diagnostic landscape.
Metropolis Q4 FY26: PAT Surges 75% to ₹51 Cr; Group Revenue Grows 23% YoY to ₹425 Cr
Metropolis Healthcare reported a robust performance for Q4 FY26, with group revenue rising 23% YoY to ₹425 Cr and PAT increasing 75% to ₹51 Cr. The organic business showed strong momentum with a 15% revenue growth and EBITDA margins expanding to 27.2% in Q4. Growth was driven by a 9.3% increase in organic patient volumes and a 5% rise in revenue per patient. The company successfully integrated three acquisitions during the year, which contributed 8% to the total FY26 revenue.
முக்கிய அம்சங்கள்
Group PAT for FY26 grew 31% YoY to ₹191 Cr on a total revenue of ₹1,646 CrOrganic EBITDA margins improved significantly to 27.2% in Q4 FY26 from 18.5% in Q4 FY25TruHealth (wellness) and Specialty segments grew by 21% and 16% respectively in FY26 (Organic)B2C revenue grew 14% YoY in FY26, supported by deeper penetration into Tier 3 marketsAcquisitions of DAPIC, Scientific Pathology, and Ambika are fully integrated; Core Diagnostics integration expected by Q1FY27
👀 கவனிக்க வேண்டியவை
Investors should view the strong margin expansion and volume-led growth as a sign of high operating leverage. The successful integration of acquisitions and the shift towards high-margin specialty and wellness tests suggest a sustainable growth trajectory.
Metropolis Healthcare FY26 Net Profit Rises 26% to ₹157 Cr; Declares ₹1 Dividend
Metropolis Healthcare reported a robust performance for FY26, with standalone revenue growing 12.3% YoY to ₹1,365.5 crore and net profit increasing by 26.4% to ₹157.1 crore. The company declared a second interim dividend of ₹1 per share, reflecting a payout on a face value of ₹2. Significant corporate changes include the transition of Dr. Nilesh Shah from President to an advisory role and the appointment of Deloitte Haskins & Sells as the new statutory auditors for a five-year term.
முக்கிய அம்சங்கள்
Standalone Revenue for FY26 increased to ₹1,365.5 crore from ₹1,215.8 crore in the previous yearNet Profit for the full year grew by 26.4% YoY, reaching ₹157.1 crore compared to ₹124.3 croreDeclared a 2nd interim dividend of ₹1 per equity share with a record date of May 19, 2026Dr. Nilesh Shah transitions from President - Internal Assurance to an advisory role effective May 14, 2026Deloitte Haskins & Sells appointed as new Statutory Auditors for 5 years, replacing B S R & Co. LLP
👀 கவனிக்க வேண்டியவை
Investors should take note of the strong double-digit profit growth and consistent dividend payouts as signs of operational efficiency. The transition of a senior leader to an advisory role and the change in auditors are routine but should be monitored for any shifts in internal governance.
Metropolis Healthcare reported a strong consolidated revenue growth of approximately 23% YoY for Q4FY26, driven by wellness and specialized testing. Organic revenue, excluding recent acquisitions, grew by 14.5% due to increased patient volumes and improved product mix. The B2B segment significantly outperformed with 30% growth, while B2C grew by 19%. Management noted improved EBITDA margins and successful integration of recent acquisitions like Core Diagnostics and DAPIC.
முக்கிய அம்சங்கள்
Consolidated revenue grew by ~23% YoY, while organic revenue rose by ~14.5% YoY.B2B revenue segment grew by ~30% YoY, outpacing B2C growth of ~19% YoY.TruHealth Wellness and Specialty segments recorded robust growth of ~25% and ~29% respectively.EBITDA margins improved YoY driven by operating leverage and efficiency gains.Core Diagnostics margins reached high single-digits, with other acquisitions delivering above-average margins.
👀 கவனிக்க வேண்டியவை
Investors should maintain a positive outlook as the company shows strong volume-led organic growth and successful inorganic integration. Watch for the full audited results to confirm the exact margin expansion and sustainability of the B2B growth momentum.
Metropolis Healthcare Allots 15.55 Crore Bonus Shares in 3:1 Ratio
Metropolis Healthcare has officially allotted 15,54,95,826 equity shares as part of its 3:1 bonus issue. Shareholders as of the record date, March 20, 2026, have been issued three new fully paid-up shares for every one share held. This corporate action has increased the company's total paid-up share capital to INR 41.47 crore. The total number of equity shares in the company now stands at 20,73,27,768, significantly enhancing the stock's liquidity in the market.
முக்கிய அம்சங்கள்
Allotment of 15,54,95,826 new equity shares of face value INR 2 each.Bonus issue executed in the ratio of 3:1 (3 new shares for every 1 existing share).Total paid-up share capital increased from previous levels to INR 41,46,55,536.Post-allotment, the total number of equity shares is 20,73,27,768.The allotment follows the record date of March 20, 2026, as per SEBI regulations.
👀 கவனிக்க வேண்டியவை
Investors should expect the new bonus shares to be credited to their demat accounts shortly; no manual action is required. While the number of shares held increases, the stock price has already adjusted proportionally, making the overall investment value neutral.
Metropolis Healthcare Sets March 20 as Record Date for 3:1 Bonus Issue
Metropolis Healthcare Limited has finalized March 20, 2026, as the record date for its 3:1 bonus share issuance. Shareholders holding the stock on this date will be eligible to receive three additional fully paid-up equity shares for every one share they currently own. This corporate action follows the board's recommendation in February 2026 and recent shareholder approval. The deemed date for the allotment of these new shares is scheduled for March 23, 2026.
முக்கிய அம்சங்கள்
Bonus issue ratio confirmed at 3:1 (3 new shares for every 1 existing share)Record date for eligibility fixed as Friday, March 20, 2026Deemed date of allotment for bonus shares is Monday, March 23, 2026Face value of shares remains unchanged at INR 2 per equity share
👀 கவனிக்க வேண்டியவை
Existing shareholders should hold their positions through the record date to qualify for the bonus; note that the share price will adjust downward proportionally on the ex-date. Potential investors should monitor the ex-date to understand the impact on liquidity and price per share.
Metropolis Shareholders Approve Bonus Share Issue with 98.36% Majority
Metropolis Healthcare Limited has received shareholder approval for the issuance of bonus shares through a postal ballot process. The resolution was passed with an overwhelming majority, with 98.36% of the total votes cast in favor of the proposal. This corporate action follows the board's recommendation in February 2026 and aims to reward shareholders while potentially increasing the stock's liquidity. The scrutinizer's report confirms that the e-voting process was conducted fairly between February 7 and March 8, 2026.
முக்கிய அம்சங்கள்
Shareholders approved the issuance of Bonus Shares with 4,69,54,514 votes in favor (98.36%).Only 1.64% of the votes (7,84,503) were cast against the ordinary resolution.The total number of equity shares as of the January 30, 2026, cut-off date was 5,18,31,942.The e-voting period concluded on March 8, 2026, with results officially declared on March 9, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming announcements for the 'Record Date' to determine eligibility for the bonus shares. The stock price will adjust proportionally on the ex-bonus date to reflect the increased share count.
Metropolis Healthcare reported a strong 26% year-on-year group revenue growth for Q3 FY26, with organic revenue increasing by 15%. A significant highlight is the Board's approval of a 3:1 bonus issue, aimed at rewarding shareholders and improving stock liquidity. Management maintained its FY26 organic growth guidance of 12-13% and expects margin expansion driven by the in-housing of high-margin genomics tests. The company is also seeing positive results from its strategic shift toward high-quality B2B and institutional partnerships.
முக்கிய அம்சங்கள்
Group revenue increased by 26% YoY in Q3 FY26, while organic revenue grew by 15% YoY.Board approved a 3:1 bonus issue (3 fully paid-up shares for every 1 existing share).Organic patient volumes grew by 9% YoY, supported by a 15% growth in the B2C segment.Core Diagnostics is expected to achieve high single-digit EBITDA margins in Q4 FY26 following the launch of in-house genomics testing.Maintained FY26 organic revenue growth guidance of 12-13% with an outlook for expanded margins.
👀 கவனிக்க வேண்டியவை
Investors should take note of the 3:1 bonus issue as a sign of management confidence and monitor the scaling of the new Centre of Genomics for margin improvements. The steady organic growth and successful integration of acquisitions suggest a robust long-term trajectory.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
